The hypertrophic-cardiomyopathy-focused biotech is led by former HI-Bio founder and CEO Travis Murdoch, M.D., while Biogen's CEO Chris Viehbacher chairs the board of directors.
<a href="https://www.fiercebiotech.com/biotech/braveheart-bio-mission-conquer-heart-disease-market-captures-185m-series" hreflang="en">Braveheart Bio launches with mission to conquer heart disease market, capturing $185M series A</a>
FierceBiotech | | Zoey Becker
Topics: oncology